REVIEW

Atopic Dermatitis and Skin Cancer Risk: A Systematic Review

Yun Zhu 💿 • Hongmei Wang • Juan He • Luhui Yang •

Xiaoyan Zhou \cdot Zhe Li \cdot Huiling Zhou \cdot Huadi Zhao \cdot Yuye Li

Received: February 23, 2022 / Accepted: March 30, 2022 / Published online: April 17, 2022 \circledcirc The Author(s) 2022

ABSTRACT

Introduction: Atopic dermatitis (AD) is one of the most common skin diseases, and it may be associated with skin cancer risk. However, there is a controversy pertaining to whether it implies a greater or decreased risk of skin cancers. We aimed to study the relationship between AD and skin cancer risk.

Methods: PubMed and Embase databases from their inception to 4 August 2021 were systematically searched.

Results: We evaluated 16 studies involving a total of 9,638,093 participants examining the contribution of AD to skin cancers. Randomeffects model was applied to estimate the overall effect sizes. The pooled analysis of 16 studies indicated that AD was significantly associated with an overall increased risk of skin cancer.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s13555-022-00720-2.

Y. Zhu

Department of Dermatology, The Sixth Affiliated Hospital of Kunming Medical University, No. 21 Nieer Road, Yuxi 653100, Yunnan, China

Y. Zhu · H. Wang · J. He · L. Yang · X. Zhou · Z. Li · H. Zhou · H. Zhao · Y. Li (\boxtimes) Department of Dermatology, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnan, China e-mail: yyeli2000@126.com Subgroup pooled analyses showed that AD was statistically associated with an increased risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). With regard to cohort study, AD was statistically associated with an increased risk of nonmelanoma skin cancer (NMSC), BCC, and SCC, but not melanoma risk. Sensitivity analysis revealed that excluding each study in turn did not alter the overall combined results. No publication bias existed among the studies. Conclusion: It can be concluded that AD is associated with risk of skin cancers: however. this association still needs to be verified in welldesigned, worldwide trials (especially prospective, non-Western studies). The mechanism of AD leading to skin cancer is not clear, and further research is needed to explore the possibility of a potential pathogenesis.

Keywords: Atopic dermatitis; Basal cell carcinoma; Skin cancer



Key Summary Points

Why carry out this study?

Atopic dermatitis is a common skin disease. To detect and prevent skin cancer earlier, we analyzed whether atopic dermatitis is a risk factor for skin cancer.

What was the hypothesis of the study?

Atopic dermatitis is a risk factor for skin cancer.

What was learned from the study?

Atopic dermatitis has the potential to predict increased risk of basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and nonmelanoma skin cancer (NMSC).

How might this affect research and/or treatment in the future?

Although the impact of atopic dermatitis on skin cancer needs to be supported by further research, this study points to a new possibility for clinical application and future research.

INTRODUCTION

Skin cancer and atopic dermatitis (AD) are among the major public health problems globally. Melanoma is an aggressive and deadly skin cancer. Nonmelanoma skin cancer (NMSC), such as squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), are also very common forms of skin cancer. AD or eczema is a chronic recurrent inflammatory skin disease associated with epithelial, immune, and environmental factors [1, 2]. It is characterized by intense itching, breakdown of the skin barrier, and activation of the type-2-mediated immune response in the skin [3, 4]. Population-based studies showed that the prevalence rate of eczema is approximately 10.7% among children and 7.2% among adults [5]. AD not only causes serious financial burden but also seriously affects the quality of patients' lives. For example, AD may be associated with skin cancer risk. Jensen et al. found an inverse association between AD and melanoma, and also found that patients with AD are at increased risk of BCC and SCC [6]. Hagströmer et al. found a nonsignificant risk elevation for nonmelanoma skin cancer [7].

Although many studies have focused on the association of AD with skin cancers [8–18], whether AD implies a greater or decreased risk of skin cancers is still controversial. Therefore, the aim of this study was to investigate the relationship between AD and the risk of skin cancers.

METHODS

The study was conducted following the *Meta-analysis of Observational Studies in Epidemiology* guidelines along with the *Preferred Reporting Items for Systematic Reviews and Meta-analyses* standards [19]. The research is registered with INPLASY202090029. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Search Strategy and Selection Criteria

We systematically searched PubMed and Embase databases on 4 August 2021, for studies performed on the relationship between AD and skin cancers. Animal studies, case reports, reviews, and meta-analyses were excluded. Our core search keywords were "Atopic dermatitis," "Eczema," "Cohort, and Case-Control Studies." The inclusion criteria were as follows: cohort and case-control studies assessing the relationship between AD and skin cancers that comprised two comparator groups, where one group had AD and the other (control) did not. Two authors (ZY and WHM) independently reviewed the titles and abstracts of the retrieved studies on the basis of the inclusion criteria. The reference lists of eligible studies or related meta-



Fig. 1 Flow diagram summarizing the pooled analysis phases (i.e., identification, screening, eligibility assessment, and ultimate inclusion)

analyses were also screened to find additional pertinent studies. The quality of the studies and risk of bias were assessed according to the Newcastle–Ottawa Scale (NOS) [20]. All disagreements were resolved by discussion with the corresponding authors.

Data Analysis

Two authors (ZY and WHM) extracted all data. When one study included more than one cohort, we pooled each cohort as an independent study. For each independent study, we recorded the following variables: first author's last name, publication year, region in which the study was performed, type of study design, type of cancer, participants' sex and age, sample size, and outcome measurements related to risk estimates with 95% confidence intervals (CIs) and adjustment factors.

A pooled analysis was conducted to explore the association between eczema and different cancers. The Cochrane Q and I^2 statistics were used to evaluate heterogeneity [21]. When either the *P*-value was < 0.1 or the I^2 value was > 50%, the data were considered to be heterogeneous, and a random-effects model [22] was applied to estimate the overall effect sizes. Otherwise, a fixed-effects model was used [23]. To further explore the origin of heterogeneity, we performed subgroup analyses by region, type of study design, and type of cancer. To assess the stability of our results, sensitivity analyses were conducted by excluding each study in turn to estimate the influence of each individual study on the pooled results. Beggar's test [24] and Egger's test [25] were used to assess

Table 1 Ch	laracté	ristics of in	cluded studi	cs							
Studics	OR	Study period	Region	Study design	Age (years)	Sex	Participants	Cancer	Statistical analysis	Adjustments	NOS score
Milán et al. [9]	1.1	1976–1999	Finland	Cohort study	18	Male and female	666	BCC	Conditional logistic regression analysis	AA	∞
Ming et al. [10]	0.85	1998–2001	USA	Case-control study	66.4 versus 60.1*	Male: 51.3% versus 39.9%	4591	NMSC	Multivariable logistic regression	Age, sex, topical steroid use, and ethnicity	۲۰ ۱
Hagströmer et al. [7]	1.5	1965–1999	Sweden	Cohort study	15.7*	Male and female	15,666	NMSC, melanoma	χ^2 test	NA	~
Olesen et al. [26]	2.4	1977–1996	Denmark	Cohort study	NA	Male and female	6275	NMSC	Poisson regression methods	NA	
Synnerstad et al. [27]	0.49	1986–2004	Sweden	Cohort study	2.6 (5.5) to 39.3 (10.9)*	Male and female	6280	Melanoma	Poisson regression analysis	Age group, sex, and year	∞
Arana et al. [28]	1.74	1992–2006	UK	Retrospective cohort study	All ages	Male and female	4,518,131	Melanoma, NMSC	Mantel-Haenszel	Age and sex	~
El-Zein et al. [11]	0.64	1979–1985	Canadian	Case-control study	35-70	Males	3809	Melanoma	Logistic regression	Age, income, respondent status, ancestry, and sports and/or outdoor activities	9
Janković et al. [12]	4.17	2006–2007	Montenegro	Case-control study	AN	Female	200	BCC	Multivariate logistic regression analysis	Age, sex, and marital status	-1
Dyer et al. [13]	1.54	ΑN	USA	Cohort study	Median age 72	Female 34 (3%) versus male 1097 (97%)	1131	BCC	Multiple logistic regression	Sex, age, education, basal cell carcinomas in prior 5 years, squamous cell carcinomas in prior 5 years, actinic keratoses at baseline, family history of skin cancer, current or former smoker	×
Jensen et al. [6]	0.59	1977–2006	Denmark	Cohort study	NA	Male and female	31,330	Melanoma, BCC, SCC	Byar's approximation	NA	8

1170

Table 1 coi	ntinue	q									
Studies	OR	Study period	Region	Study design	Age (years)	Sex	Participants	Cancer	Statistical analysis	Adjustments	NOS score
Hajdarbegovic et al. [14]	1.05	2000–2010	Netherlands	Case-control study	57 土 14 versus 56 土 14*	Male and female	353	Melanoma	Logistic multiple regression analysis	Unadjusted OR	7
Cheng et al. [15]	1.83	AN	USA	Case-control study	25-74	Female	1312	SCC	Multiple logistic regression	Age, gender, and skin reaction to the first hour of sunlight during summer (blister, painful sunburn followed by peeling mild sunburn followed by tanning, tanning with no sunburn)	×
	1.52	NA	USA	Case-control study	25-74	Female	NA	BCC	Multiple logistic regression	Age, gender, and skin reaction to the first hour of sunlight during summer (blister, painful sunburn followed by peeling mild sunburn followed by tanning, tanning with no sunburn)	×
Marasigan et al. [16]	0.46	ΥN	Belgium	Case-control study	57.4* for controls, 52.2* for cases	Male and female	232	Melanoma	Conditional logistic regression	Age, sex, sunburn sensitivity, hair color, number of moles, sunburn as juvenile, ever sunbed use, familial melanoma	×
Cho et al. [8]	1.75	1996–2010	USA	Case-control study	69.6 (13.5) versus 69.5 (13.5)*	Female	1179	SCC	Logistic regression analysis	Race, smoking history, ionizing radiation exposure, corticosteroid and cyclosporine use, non-SCC skin cancers, odds ratio for SCC development	6
D'Arcy et al. [17]	1.07	1992–2013	USA	Case-control study	6699	Female	1,844,575	Melanoma	Logistic regression analysis	Sex, age, race, calendar year of selection, and measures of socioeconomic status and healthcare utilization	7
Mansfield et al. [31]	0.96	1998–2016	UK	Cohort study	41.1 [24.9–60.7] versus 39.8 [25.9–58.4]#	Female	2,711,745	Melanoma	Cox proportional hazards regression model	Sex, primary care practice, date, and age	×
	1.1	1998–2016	UK	Cohort study	41.1 [24.9–60.7] versus 39.8 [25.9–58.4]#	Female	NA	NMSC	Cox proportional hazards regression model	Sex, primary care practice, date, and age	∞

Studies 0.	R Study period	Region	Study design	Age (years)	Sex	Participants	Cancer	Statistical analysis	Adjustments	NOS score
9 ⁷ 0	it 1982-2014	5 Denmark	Cohort study	13.7 [1.7–21.1] versus 13.5 [1.7–20.8]#	Female	490,618	Melanoma	Cox proportional hazards regression model	Sex, date, and age	∞
	7 1982-201	5 Denmark	Cohort study	13.7 [1.7–21.1] versus 13.5 [1.7–20.8]#	Female	NA	NMSC	Cox proportional hazards regression model	Sex, date, and age	∞

negian

Dermatol Ther (Heidelb) (2022) 12:1167-1179

potential publication bias. STATA software v12.0 (College Station, TX, USA) was used to analyze the data.

RESULTS

Search Results and Study Characteristics

A total of 493 studies were retrieved from the PubMed and the Embase databases, and after removing 51 duplicates and further excluding 405 studies after title and abstract screening and 27 on the basis of the full article, 10 studies remained. However, six additional eligible studies were identified after screening the references of relevant studies. As a result, 16 studies [6-18, 26-28], involving a total of 9,638,093 participants, that examined the contribution of AD to skin cancers eventually fulfilled the established criteria (Fig. 1). Details on the characteristics of the studies are summarized in Table 1, and assessments of the studies are summarized in Table S1 in the Supplementary Material. Eight population-based cohort studies [6, 7, 9, 13, 18, 26-28], and eight case-control studies were included in this analysis [8, 10–12, 14–17]. Of these, one is from Finland [9], two from Sweden [7, 27], three from Denmark [6, 18, 26], four from USA [8, 10, 13, 15, 17], one from Belgium [16], one from Canada [11], one from Montenegro [12], one from Netherlands [14], and two from UK [18, 28].

Qualitative Analysis

Firstly, the pooled analysis of 16 studies [6-18, 26-28] indicated that AD was significantly associated with an increased risk of overall skin cancer (OR 1.18, 95% CI 1.06-1.32); moreover, substantial heterogeneity was $(P_{\text{heterogeneity}} = 0.000,$ $I^2 = 73.4\%$ observed (Fig. 2a). Subgroup pooled analyses were performed according to cancer type, study design, and region, and we found that AD was significantly associated with an increased risk of overall skin cancer in the following subgroups: NMSC subgroup: OR 1.39, 95% CI 1.20-1.61

u	
Study	ES (95% CI) Weight%
Milan(M),2003	1.10 (0.47, 2.59) 1.46
Milan(F).2003	1.80 (0.83, 3.90) 1.72
Ming,2004	0.85 (0.67, 1.08) 6.76
Hagstromer-N,2005	1.50 (0.80, 2.60) 2.63
Hagstromer-M.2005	0.60 (0.30, 1.20) 2.05
Olesen 2005	240(140,390) 3.20
Synperstad 2008	0.49 (0.27, 1.35) 1.61
Arana-M 2010	1 74 (1 25 2 41) 5 30
Arapa-N 2010	146 (127 169) 843
FI-7ein 2010	0.64 (0.20, 2.20) 0.80
lankovic 2010	- 4 17 (1 53 11 39) 1 10
Dver 2012	
Jensen-M 2012	0.59 (0.30, 1.02) 2.48
Jensen-B 2012	1 41 (1 07 1 83) 6.25
lensen-S 2012	2 48 (1 00 5 11) 1.57
Haidarbegovic 2014	1 05 (0 50 2 23) 1 82
Cheng_S 2015	183 (0.97, 3.45) 2.35
Cheng-B 2015	1 52 (0 77 3 01) 2.10
Marasigan 2017	0.46 (0.16, 1.31) 1.01
Cho 2018	1 75 (1 05 2 93) 3 19
D'Aroy 2019	1.07 (0.04 1.22) 8.63
Mansfield-LIM 2020	0.96 (0.86 1.07) 8.94
Mansheld UN 2020	1 10 (1 06 1 14) 967
Mansheld_DM 2020	0.64 (0.44, 0.93) 4.66
Mansfield-DN 2020	1 17 (0 99 1 38) 8 04
Overall (Leguared = 73.4% p = 0.000)	1 18 (1 06 1 32) 100 00
Overall (I-squared = 73.4%, p = 0.000)	1.18 (1.00, 1.32) 100.00
.0878 1	11.4
•	
C	
Study	ES (95% CI) Weight%
Milan(M),2003	1.10 (0.47, 2.59) 1.46
Milan(M),2003	1.10 (0.47, 2.59) 1.46 1.80 (0.83, 3.90) 1.72
Milan(M),2003	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63
Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Hagstromer–M 2005	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05
Milan(M),2003	1.10 (0.47, 2.59) 1.46 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 - 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30
Milan(F),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Arana–N,2010	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Arana–N,2012	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.66 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Arana–N,2010 Dyer,2012 Lensen–M,2012	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48
Milan(F),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Dyer,2012 Jensen–M,2012 Jensen–M,2012	- 1.10 (0.47, 2.59) 1.46 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.35
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Arana–N,2010 Dyer,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.25 2.48 (1.40, 511) 1.57
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Dyer,2012 Jensen–M,2012 Jensen–M,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 - 240 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.25 2.48 (1.00, 5.11) 1.57 0.96 (0.96 1.07) 8.44
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Arana–N,2010 Dyer,2012 Jensen–M,2012 Jensen–B,2012 Jensen–S,2012 Mansfield–UM,2020	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 - 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.25 2.48 (1.00, 5.11) 1.57 0.96 (0.86, 1.07) 8.94
Milan(M),2003 Milan(F),2003 Hagstromer–M,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Arana–N,2010 Dyer,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Mansfield–UM,2020 Mansfield–UM,2020	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.25 2.48 (1.40, 5.11) 1.57 0.96 (0.86, 1.07) 8.94 1.10 (1.06, 1.14) 9.67
Milan(M),2003 Milan(F),2003 Hagstromer–M,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Dyer,2012 Jensen–M,2012 Jensen–B,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–J,2012 Jensen–S,2012 Mansfield–UM,2020 Mansfield–UM,2020	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (107, 1.83) 6.25 2.48 (1.00, 5.11) 1.57 0.96 (0.86, 1.07) 8.94 1.10 (1.06, 1.14) 9.67 0.64 (0.44, 0.93) 4.66
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Dyer,2012 Jensen–M,2012 Jensen–M,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–M,2010 Mansfield–UN,2020 Mansfield–DN,2020	- 1.10 (0.47, 2.59) 1.46 - 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 - 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.25 2.48 (1.00, 5.11) 1.57 0.96 (0.86, 1.07) 8.94 1.10 (1.06, 1.14) 9.67 0.64 (0.44, 0.93) 4.66 1.17 (0.99, 1.38) 8.04
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Dyer,2012 Jensen–A,2012 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Mansfield–UN,2020 Mansfield–UN,2020 Mansfield–DN,2020 Subtotal (I–squared = 78.1%, p = 0.000)	 1.10 (0.47, 2.59) 1.46 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.25 2.48 (1.00, 5.11) 1.57 0.96 (0.86, 1.07) 8.94 1.10 (1.06, 1.14) 9.67 0.64 (0.44, 0.93) 4.66 1.17 (0.99, 1.38) 8.04 Cohort study 1.19 (1.04, 1.37) 72.25
Milan(M),2003 Milan(F),2003 Hagstromer–M,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Dyer,2012 Jensen–M,2012 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Jensen–S,2012 Mansfield–UM,2020 Mansfield–UM,2020 Mansfield–UM,2020 Mansfield–UM,2020 Subtotal (I-squared = 78.1%, p = 0.000) Ming,2004	 1.10 (0.47, 2.59) 1.46 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.66 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.25 2.48 (1.00, 5.11) 1.57 0.96 (0.86, 1.07) 8.94 1.10 (1.06, 1.14) 9.67 0.64 (0.44, 0.93) 4.66 1.17 (0.99, 1.38) 8.04 Cohort study 1.19 (1.04, 1.37) 7.225 0.85 (0.67, 1.08) 6.76
Milan(M),2003 Milan(F),2003 Hagstromer–M,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Dyer,2012 Jensen–M,2012 Jensen–M,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Mansfield–UM,2020 Mansfield–UM,2020 Mansfield–UN,2020 Mansfield–UN,2020 Jubtotal (I-squared = 78.1%, p = 0.000) Ming,2004 El–Zein,2010	 1.10 (0.47, 2.59) 1.46 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.66 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 4.26 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.25 2.48 (1.00, 5.11) 1.57 0.96 (0.86, 1.07) 8.94 1.10 (1.06, 1.14) 9.67 0.64 (0.44, 0.93) 4.66 1.17 (0.99, 1.38) 8.04 Cohort study 1.19 (1.04, 1.37) 72.25 0.85 (0.67, 1.08) 6.76 0.64 (0.20, 2.20) 0.80
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Dyer,2012 Jensen–M,2010 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Mansfield–UN,2020 Mansfield–UN,2020 Mansfield–DN,2020 Subtotal (I–squared = 78.1%, p = 0.000) Subtotal (I–squared = 78.1%, p = 0.000) Ming,2004 EI–Zein,2010 Jankovic,2010	$\begin{array}{c} 1.10 \ (0.47, 2.59) \ 1.46 \\ 1.80 \ (0.83, 3.90) \ 1.72 \\ 1.50 \ (0.80, 2.60) \ 2.63 \\ 0.60 \ (0.30, 1.20) \ 2.05 \\ 2.40 \ (1.40, 3.90) \ 3.20 \\ 0.49 \ (0.27, 1.35) \ 1.61 \\ 1.74 \ (1.25, 2.41) \ 5.30 \\ 1.46 \ (1.27, 1.69) \ 8.43 \\ 1.54 \ (1.03, 2.32) \ 4.26 \\ 0.59 \ (0.30, 1.02) \ 2.48 \\ 1.41 \ (1.07, 1.83) \ 6.25 \\ 2.48 \ (1.00, 5.11) \ 1.57 \\ 0.96 \ (0.86, 1.07) \ 8.94 \\ 1.10 \ (1.06, 1.14) \ 9.67 \\ 0.64 \ (0.24, 0.93) \ 4.66 \\ 1.17 \ (0.99, 1.38) \ 8.04 \\ \hline \textbf{Cohort study} \ 1.19 \ (1.04, 1.37) \ 72.25 \\ 0.88 \ (0.67, 1.08) \ 6.76 \\ 0.64 \ (0.20, 2.20) \ 0.80 \\ \hline \bullet \ 4.17 \ (1.55, 11.39) \ 1.10 \\ \hline \end{array}$
Milan(M),2003 Milan(F),2003 Hagstromer–M,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Dyer,2012 Jensen–M,2010 Dyer,2012 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Mansfield–UM,2020 Mansfield–UM,2020 Mansfield–DM,2020 Subtotal (I-squared = 78.1%, p = 0.000) Ming,2004 EI-Zein,2010 Jankovic,2010 Hajdarbegovic,2014	$\begin{array}{c} 1.10 \ (0.47, 2.59) \ 1.46 \\ \hline 1.80 \ (0.83, 3.90) \ 1.72 \\ 1.50 \ (0.80, 2.60) \ 2.63 \\ 0.60 \ (0.30, 1.20) \ 2.05 \\ \hline 2.40 \ (1.40, 3.90) \ 3.20 \\ 0.49 \ (0.27, 1.35) \ 1.61 \\ 1.74 \ (1.25, 2.41) \ 5.30 \\ 1.46 \ (1.27, 1.69) \ 8.43 \\ 1.54 \ (1.03, 2.32) \ 4.26 \\ 0.59 \ (0.30, 1.02) \ 2.48 \\ 1.41 \ (1.07, 1.83) \ 6.25 \\ 2.48 \ (1.00, 5.11) \ 1.57 \\ 0.96 \ (0.86, 1.07) \ 8.94 \\ 1.10 \ (1.06, 1.14) \ 9.67 \\ 0.64 \ (0.44, 0.93) \ 4.66 \\ 1.17 \ (0.99, 1.38) \ 8.04 \\ \hline Cohort study \ 1.19 \ (1.04, 1.37) \ 72.25 \\ \hline 0.85 \ (0.67, 1.08) \ 6.76 \\ 0.64 \ (0.20, 2.20) \ 0.80 \\ \hline 4.17 \ (1.53, 11.39) \ 1.10 \\ 1.05 \ (0.50, 2.23) \ 1.82 \\ \hline \end{array}$
Milan(M),2003 Milan(F),2003 Hagstromer–M,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Dyer,2012 Jensen–M,2010 Dyer,2012 Jensen–M,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Mansfield–UM,2020 Mansfield–UM	$\begin{array}{c} 1.10 \ (0.47, 2.59) \ 1.46 \\ \hline \\ 1.80 \ (0.83, 3.90) \ 1.72 \\ 1.50 \ (0.80, 2.60) \ 2.63 \\ 0.66 \ (0.30, 1.20) \ 2.05 \\ \hline \\ 2.40 \ (1.40, 3.90) \ 3.20 \\ 0.49 \ (0.27, 1.35) \ 1.61 \\ 1.74 \ (1.25, 2.41) \ 5.30 \\ 1.46 \ (1.27, 1.69) \ 8.43 \\ 1.54 \ (1.03, 2.32) \ 4.26 \\ 0.59 \ (0.30, 1.02) \ 2.48 \\ 1.41 \ (1.07, 1.83) \ 6.25 \\ 2.48 \ 1.41 \ (1.07, 1.83) \ 6.25 \\ 2.48 \ 1.00 \ 5.11) \ 1.57 \\ 0.96 \ (0.86, 1.07) \ 8.94 \\ 1.10 \ (1.06, 1.14) \ 9.67 \\ 0.64 \ (0.44, 0.93) \ 4.66 \\ 1.17 \ (0.99) \ 1.38) \ 8.04 \\ \hline \\ Cohort study \ 1.19 \ (1.04, 1.37) \ 72.25 \\ \hline \\ 0.85 \ (0.67, 1.08) \ 6.76 \\ 0.64 \ (0.20, 2.20) \ 0.80 \\ \hline \\ 1.71 \ (1.53, 11.39) \ 1.10 \\ 1.05 \ (0.50, 2.23) \ 1.82 \\ \hline \\ 1.83 \ (0.97, 3.45) \ 2.35 \\ \hline \end{array}$
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Dyer,2012 Jensen–M,2010 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Mansfield–UN,2020 Mansfield–UN,2020 Mansfield–DN,2020 Subtotal (I-squared = 78.1%, p = 0.000) Subtotal (I-squared = 78.1%, p = 0.000) Ming,2004 EI–Zein,2010 Jankovic,2010 Hajdarbegovic,2014 Cheng–B,2015 Cheng–B,2015	$\begin{array}{c} 1.10 \ (0.47, 2.59) \ 1.46 \\ 1.80 \ (0.83, 3.90) \ 1.72 \\ 1.50 \ (0.80, 2.60) \ 2.63 \\ 0.60 \ (0.30, 1.20) \ 2.05 \\ 2.40 \ (1.40, 3.90) \ 3.20 \\ 0.49 \ (0.27, 1.35) \ 1.61 \\ 1.74 \ (1.25, 2.41) \ 5.30 \\ 1.46 \ (1.27, 1.69) \ 8.43 \\ 1.54 \ (1.03, 2.32) \ 4.26 \\ 0.59 \ (0.30, 1.02) \ 2.48 \\ 1.41 \ (1.07, 1.83) \ 6.25 \\ 4.48 \ (1.00, 5.11) \ 1.57 \\ 0.96 \ (0.86, 1.07) \ 8.94 \\ 1.10 \ (1.06, 1.14) \ 9.67 \\ 0.64 \ (0.24, 0.93) \ 4.66 \\ 1.17 \ (0.99, 1.38) \ 8.04 \\ \hline \textbf{Cohort study} \ 1.19 \ (1.04, 1.37) \ 72.25 \\ \hline 0.85 \ (0.67, 1.08) \ 6.76 \\ 0.64 \ (0.20, 2.20) \ 0.80 \\ \hline \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$
Milan(M),2003 Milan(F),2003 Hagstromer–M,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Arana–N,2010 Dyer,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Mansfield–UM,2020 Mansfield–UM,2020 Mansfield–DM,2020 Mansfield–DN,2020 Subtotal (I–squared = 78.1%, p = 0.000) Ming,2004 EI–Zein,2010 Jankovic,2010 Haidarbegovic,2014 Cheng–S,2015 Marsigan,2017 Massigan,2017	$\begin{array}{c} 1.10 \ (0.47, 2.59) \ 1.46 \\ 1.80 \ (0.83, 3.90) \ 1.72 \\ 1.50 \ (0.80, 2.60) \ 2.63 \\ 0.60 \ (0.30, 1.20) \ 2.05 \\ 2.40 \ (1.40, 3.90) \ 3.20 \\ 0.49 \ (0.27, 1.35) \ 1.61 \\ 1.74 \ (1.25, 2.41) \ 5.30 \\ 1.46 \ (1.27, 1.69) \ 8.43 \\ 1.54 \ (1.03, 2.32) \ 4.26 \\ 0.59 \ (0.30, 1.02) \ 2.48 \\ 1.41 \ (1.07, 1.83) \ 6.25 \\ 2.48 \ (1.00, 5.11) \ 1.57 \\ 0.96 \ (0.86, 1.07) \ 8.94 \\ 1.10 \ (1.06, 1.14) \ 9.67 \\ 0.64 \ (0.44, 0.93) \ 4.66 \\ 1.17 \ (0.99, 1.38) \ 8.04 \\ \hline \textbf{Cohort study} \ 1.19 \ (1.04, 1.37) \ 72.25 \\ \hline 0.68 \ (0.67, 1.08) \ 6.76 \\ 0.64 \ (0.20, 2.20) \ 0.80 \\ \hline 1.17 \ (0.59, 1.13) \ 1.10 \\ 1.05 \ (0.50, 2.23) \ 1.82 \\ \hline - \ 1.83 \ (0.97, 3.45) \ 2.35 \\ - \ 1.52 \ (0.77, 3.01) \ 2.10 \\ 0.46 \ (0.16, 1.31) \ 1.01 \\ 1.05 \ (2.92) \ 3.19 \\ \hline \end{array}$
Milan(M),2003 Milan(F),2003 Hagstromer–M,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Dyer,2012 Jensen–M,2012 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Mansfield–UM,2020 M	$\begin{array}{c} 1.10 \ (0.47, 2.59) \ 1.46 \\ \hline 1.80 \ (0.83, 3.90) \ 1.72 \\ 1.50 \ (0.80, 2.60) \ 2.63 \\ 0.66 \ (0.30, 1.20) \ 2.05 \\ \hline 2.40 \ (1.40, 3.90) \ 3.20 \\ 0.49 \ (0.27, 1.35) \ 1.61 \\ 1.74 \ (1.25, 2.41) \ 5.30 \\ 1.46 \ (1.27, 1.69) \ 8.43 \\ 1.54 \ (1.03, 2.32) \ 4.26 \\ 0.59 \ (0.30, 1.02) \ 2.48 \\ 1.41 \ (1.07, 1.83) \ 6.25 \\ 2.48 \ (1.00, 5.11) \ 1.57 \\ 0.96 \ (0.36, 1.07) \ 8.94 \\ 1.10 \ (1.06, 1.14) \ 9.67 \\ 0.64 \ (0.44, 0.93) \ 4.66 \\ 1.17 \ (0.99, 1.38) \ 8.04 \\ \hline Cohort study \ 1.19 \ (1.04, 1.37) \ 7.225 \\ \hline 0.88 \ (0.67, 1.08) \ 6.76 \\ 0.64 \ (0.20, 2.20) \ 0.80 \\ \hline 1.10 \ (1.53, 11.39) \ 1.10 \\ 1.05 \ (0.50, 2.23) \ 1.82 \\ \hline 1.83 \ (0.97, 3.45) \ 2.35 \\ \hline 1.57 \ (1.55, 2.73 \ 0.11) \ 1.10 \\ 1.65 \ (1.55, 2.73 \ 0.11) \ 1.10 \\ 1.75 \ (1.05, 2.23) \ 3.19 \\ \hline 1.77 \ (1.05, 2.13) \ 3.19 \\ \hline 1.77 \ (1.05, 2.43) \ 3.19 $
Milan(F),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Dyer,2012 Jensen–M,2010 Dyer,2012 Jensen–M,2010 Jensen–M,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Mansfield–UN,2020 Mansfield–UN,2020 Mansfield–DN,2020 Subtotal (I-squared = 78.1%, p = 0.000) Ming,2004 EI–Zein,2010 Jankovic,2010 Hajdarbegovic,2014 Cheng–S,2015 Cheng–S,2015 Cheng–S,2015 Cheng–S,2015 Cheng–S,2015 Cheng–S,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2014 Cheng–B,2015 Cheng–B,2	$\begin{array}{c} 1.10 \ (0.47, 2.59) \ 1.46 \\ 1.80 \ (0.83, 3.90) \ 1.72 \\ 1.60 \ (0.80, 2.60) \ 2.63 \\ 0.60 \ (0.30, 1.20) \ 2.05 \\ 2.40 \ (1.40, 3.90) \ 3.20 \\ 0.49 \ (0.27, 1.35) \ 1.61 \\ 1.74 \ (1.25, 2.41) \ 5.30 \\ 1.46 \ (1.27, 1.69) \ 8.43 \\ 1.54 \ (1.03, 2.32) \ 4.26 \\ 0.59 \ (0.30, 1.02) \ 2.48 \\ 1.41 \ (1.07, 1.83) \ 6.25 \\ 2.48 \ (1.00, 5.11) \ 1.57 \\ 0.96 \ (0.86, 1.07) \ 8.94 \\ 1.10 \ (1.06, 1.14) \ 9.67 \\ 0.64 \ (0.44, 0.93) \ 4.66 \\ 1.17 \ (0.99, 1.38) \ 8.04 \\ \hline Cohort study \ 1.19 \ (1.04, 1.37) \ 72.25 \\ \hline 0.85 \ (0.67, 1.08) \ 6.76 \\ 0.64 \ (0.24, 2.20) \ 0.80 \\ \hline 4.17 \ (1.53, 11.39) \ 1.10 \\ 1.05 \ (0.50, 2.23) \ 1.82 \\ \hline - \ 1.52 \ (0.77, 3.01) \ 2.10 \\ 0.46 \ (0.16, 1.31) \ 1.01 \\ - \ 1.75 \ (1.05, 2.93) \ 3.19 \\ 1.07 \ (0.94, 1.22) \ 8.63 \\ \hline case-control \ 1.20 \ (0.27, 55) \ 7.75 \\ \hline \end{array}$
Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Dyer,2012 Jensen–S,2012 Jensen–S,2012 Jensen–S,2012 Mansfield–UN,2020 Mansfield–UN,2020 Mansfield–UN,2020 Subtotal (I-squared = 78.1%, p = 0.000) Ming,2004 EI–Zein,2010 Jankovic,2010 Hajdarbegovic,2014 Cheng–S,2015 Cheng–B,2015 Maraigan,2017 Cheng–B,2015 Maraigan,2017 Cheng–B,2015 Maraigan,2017 Cheng–B,2015 Maraigan,2017 Cheng–B,2015 Cheng–B,2015 Maraigan,2017 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Cheng–B,2015 Maraigan,2017 Cheng–S,2016 Cheng–S,2017 Cheng–C,2018 D'Arcy,2019 Subtotal (I-squared = 62.1%, p = 0.007) Cheng–C,2018 D'Arcy,2019 Subtotal (I-squared = 62.1%, p = 0.007) Cheng–C,2018 D'Arcy,2019 Subtotal (I-squared = 73.4%, p = 0.0007) Cheng–C,2018 Cheng–C,201	1.10 (0.47, 2.59) 1.46 1.80 (0.83, 3.90) 1.72 1.50 (0.80, 2.60) 2.63 0.60 (0.30, 1.20) 2.05 2.40 (1.40, 3.90) 3.20 0.49 (0.27, 1.35) 1.61 1.74 (1.25, 2.41) 5.30 1.46 (1.27, 1.69) 8.43 1.54 (1.03, 2.32) 2.426 0.59 (0.30, 1.02) 2.48 1.41 (1.07, 1.83) 6.25 2.48 (1.00, 5.11) 1.57 0.96 (0.86, 1.07) 8.94 1.10 (1.06, 1.14) 9.67 0.64 (0.44, 0.93) 4.66 1.17 (0.99, 1.38) 8.04 Cohort study 1.19 (1.04, 1.37) 72.25 0.85 (0.67, 1.08) 6.76 0.64 (0.20, 2.20) 0.80 4.17 (1.53, 11.39) 1.10 1.05 (0.50, 2.23) 1.82 - 1.83 (0.97, 3.45) 2.35 - 1.52 (0.77, 3.01) 2.10 0.46 (0.16, 1.31) 1.01 1.07 (0.94, 1.22) 8.63 case-control 1.20 (0.92, 1.56) 27.75 1.81 (0.67, 1.32) 100.00
Milan(M),2003 Milan(F),2003 Hagstromer–M,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Dyer,2012 Jensen–M,2010 Dyer,2012 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Mansfield–UM,2020 Mansfield–UM,2020 Mansfield–DM,2020 Subtotal (I–squared = 78.1%, p = 0.000) Ming,2004 EI–Zein,2010 Jankovic,2010 Hajdarbegovic,2014 Cheng–S,2015 Cheng–S,2015 Maraigan,2017 Cho,2018 D'Ary,2019 Subtotal (I–squared = 62.1%, p = 0.000) Overall (I–squared = 73.4%, p = 0.000)	$\begin{array}{c} 1.10 \ (0.47, 2.59) \ 1.46 \\ 1.80 \ (0.83, 3.90) \ 1.72 \\ 1.50 \ (0.80, 2.60) \ 2.63 \\ 0.60 \ (0.30, 1.20) \ 2.05 \\ 2.40 \ (1.40, 3.90) \ 3.20 \\ 0.49 \ (0.27, 1.35) \ 1.61 \\ 1.74 \ (1.25, 2.41) \ 5.30 \\ 1.46 \ (1.27, 1.69) \ 8.43 \\ 1.54 \ (1.03, 2.32) \ 4.26 \\ 0.59 \ (0.30, 1.02) \ 2.48 \\ 1.41 \ (1.07, 1.83) \ 6.25 \\ 2.48 \ (1.00, 5.11) \ 1.57 \\ 0.96 \ (0.86, 1.07) \ 8.94 \\ 1.10 \ (1.06, 1.14) \ 9.67 \\ 0.64 \ (0.44, 0.93) \ 4.66 \\ 1.17 \ (0.99, 1.38) \ 8.04 \\ \hline Cohort study \ 1.19 \ (1.04, 1.37) \ 72.25 \\ 0.85 \ (0.67, 1.08) \ 6.76 \\ 0.64 \ (0.20, 2.20) \ 0.80 \\ \hline \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$

Fig. 2 Estimated effects of AD on skin cancer risk. **a** Forest plot for effects of AD on skin cancer risk. **b** Forest plot for subgroup analysis by cancer type. **c** Forest plot for

(Fig. 2b), cohort study subgroup: OR 1.19, 95% CI 1.04–1.37 (Fig. 2c), American subgroup: OR 1.32, 95% CI 1.02–1.71 (Fig. 2d), and Europe subgroup: OR, 1.15; 95% CI, 1.01–1.32 (Fig. 2d), but not melanoma subgroup: OR 0.89, 95% CI 0.73–1.09 (Fig. 2b).

Study	ES (95% CI)	Weight%
Milan(M),2003	• 1.10 (0.47	, 2.59) 1.46
Milan(F),2003 –	1.80 (0.83	, 3.90) 1.72
Ming,2004 -+	0.85 (0.67	, 1.08) 6.76
Hagstromer–N,2005 –	1.50 (0.80	, 2.60) 2.63
Olesen,2005	2.40 (1.40	, 3.90) 3.20
Arana–N,2010	+ 1.46 (1.27	, 1.69) 8.43
Jankovic,2010	▲ → 4.17 (1.53	, 11.39) 1.10
Dyer,2012	1.54 (1.03	,2.32) 4.26
Jensen–B,2012	1.41 (1.07	, 1.83) 6.25
Jensen-S,2012 Change S 2015	2.48 (1.00	(3.11) 1.57
Cheng_B 2015	1.83 (0.97	3.43) 2.33
Cho 2018	1.52 (0.77	293) 319
Mansfield-LIN 2020	1 10 (1.05	1 14) 967
Mansfeld DN 2020	1.10 (1.00	1.130) 0.04
$\left[\frac{1}{2} \frac$	NMSC 1 20 (1 20	1 61) 60 71
Subtotal (1-squared = 72.7%, p = 0.000)	1.39(1.20	(, 1.01) 02.71
Hagstromer–M,2005	0.60 (0.30	1, 1.20) 2.05
Arana-M 2010		, 1.33) 1.01
Fl_Zein 2010	1.74(1.2	0, 2.41) 5.50
lensen-M.2012	0.59 (0.30	0.1.02) 2.48
Haidarbegovic.2014	1.05 (0.50), 2.23) 1.82
Marasigan,2017	0.46 (0.16	5, 1.31) 1.01
D'Arcy,2019	+ 1.07 (0.94	4, 1.22) 8.63
Mansfield–UM.2020	• 0.96 (0.86	5. 1.07) 8.94
Mansfield–DM.2020	0.64 (0.44	1.0.93) 4.66
Subtotal (I-squared = 68.4%, p = 0.001)	Melanoma 0.89 (0.73	3, 1.09) 37.29
Overall (I-squared = 73.4%, p = 0.000)	0 1.18 (1.06	5. 1.32) 100.00
.0878	1 11.4	
d		
u		
Study	ES (95% CI)	Weight%
Study	ES (95% CI)	Weight%
Study Milan(M),2003	ES (95% CI)	Weight% 7, 2.59) 1.46
Study Milan(M),2003	ES (95% CI)	Weight% 7, 2.59) 1.46 3, 3.90) 1.72
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005	ES (95% CI) 1.10 (0.4: 1.80 (0.8 1.50 (0.80	Weight% 7, 2.59) 1.46 3, 3.90) 1.72 0, 2.60) 2.63
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005	ES (95% CI) 1.10 (0.4: 1.80 (0.8: 1.50 (0.8: 0.60 (0.3:	Weight% 7, 2.59) 1.46 3, 3.90) 1.72 0, 2.60) 2.63 0, 1.20) 2.05
Study Milan(M),2003 Milan(F),2003 Higstromer–N,2005 Hagstromer–M,2005 Olesen,2005	ES (95% Cl)	Weight% 7, 2.59) 1.46 3, 3.90) 1.72 0, 2.60) 2.63 0, 1.20) 2.05 0, 3.90) 3.20
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008	ES (95% Cl) 1.10 (0.4 1.80 (0.8 0.60 (0.3 0.60 (0.3 0.40 (0.2)	Weight% 7, 2.59) 1.46 3, 3.90) 1.72 0, 2.60) 2.63 0, 1.20) 2.05 0, 3.90) 3.20 7, 1.35) 1.61
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010	ES (95% Cl) 1.10 (0.4 1.80 (0.8 1.50 (0.8 0.60 (0.3 0.60 (0.3 0.49 (0.2 1.74 (1.2)	Weight% 7, 2.59) 1.46 3, 3.90) 1.72 0, 2.60) 2.63 0, 1.20) 2.05 0, 3.90) 3.20 7, 1.35) 1.61 5, 2.41) 5.30
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Arana–N,2010	ES (95% Cl) 1.10 (0.4 1.80 (0.8 1.50 (0.8) 0.60 (0.3) 0.60 (0.3) (0.6) (0.5) (0.6) (0.5) (0.6) (0.5) (0.6) (0.5) (0.6) (0.5) (0.6) (0.5) (0.6) (0.6) (0.5) (0.6) (0.5) (0.6) (0	Weight% 7, 2.59) 1.46 3, 3.90) 1.72 0, 2.60) 2.63 0, 1.20) 2.05 0, 3.90) 3.20 7, 1.35) 1.61 5, 2.41) 5.30 7, 1.69) 8.43
Study Milan(M),2003	ES (95% Cl) 1.10 (0.4 1.80 (0.8 0.60 (0.3) 2.40 (1.4 0.49 (0.2) 1.74 (1.2) 0.59 (0.3)	Weight% 7, 2.59 1.46 3, 3.90) 1.72 0, 2.60) 2.63 0, 1.20) 2.05 0, 3.90) 3.20 7, 1.35) 1.61 5, 2.41) 5.30 7, 1.69 8.43 0, 1.02) 2.48
Study Milan(M),2003	ES (95% Cl) 1.10 (0.4 1.80 (0.8 1.50 (0.8 0.60 (0.3 0.60 (0.3 0.49 (0.2 1.74 (1.2 1.46 (1.2 0.59 (0.3 0.59 (0.3 0.49 (0.2) 1.41 (1.2)	Weight% 7, 2:59 1.46 3, 3:90 1.72 0, 2:60 2:63 0, 1.20 2:05 0, 3:90 3:20 7, 1.35 1.61 5, 2:41) 5:30 7, 1.69 8:43 7, 1.69 2:48 7, 1.83 6:25
Study Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Hagstromer–M, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–B, 2012 Jensen–S, 2012	ES (95% Cl) 1.10 (0.4 1.80 (0.8 0.60 (0.3 0.60 (0.3 0.60 (0.3 0.60 (0.3 0.60 (0.3 0.49 (0.2 1.74 (1.2 1.74 (1.2 0.59 (0.3) 1.46 (1.2) 0.59 (0.3 1.41 (1.0) 0.59 (0.3)	Weight% 7, 2:59 1.46 3, 3:90 1.72 3, 2:60 2.63 0, 1:20 2.05 0, 3:90 3.20 1, 1:35 1.61 5, 2:41 5.30 7, 1:59 8.43 7, 1:69 8.43 7, 1:83 6.25 5, 5:11 1.57
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Hajdstroeqovic,2014	ES (95% Cl)	Weight% 7, 2.59) 1.46 3, 3.90) 1.72 0, 2.60) 2.63 1, 1.20) 2.05 0, 3.90) 3.20 7, 1.39) 3.20 7, 1.39) 3.20 7, 1.39) 3.20 7, 1.39) 3.20 7, 1.39) 3.20 7, 1.39) 8.43 0, 1.02) 2.48 7, 1.83) 6.25 0, 5.11) 1.57 0, 2.23) 1.82
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Jensen–B,2012 Jensen–S,2012 Jensen–S,2012 Hajdarbegovic,2014 Marasigan,2017	ES (95% CI) 1.10 (0.4 1.80 (0.8 1.50 (0.8(0.60 (0.3(0.49 (0.2) 1.74 (1.2) 1.74 (1	Weight% 7, 2:59) 1:46 3, 3:90) 1.72 0, 2:60) 2:63 0, 1.20) 2:05 0, 3:30) 3:20 7, 1:35) 1:61 5, 2:41) 5:30 7, 1:69) 8:43 7, 1:69) 8:43 7, 1:63) 6:25 0, 5:11) 1.57 0, 2:23) 1.82 0, 2:23) 1.82
Study Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Hagstromer–M, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–M, 2012 Jensen–B, 2012 Jensen–S, 2012 Hajdarbegovic, 2014 Marasigan, 2017 Mansfield–UM, 2020	ES (95% Cl) 1.10 (0.4 1.00 (0.3 1.50 (0.8 0.60 (0.3 0.60 (0.3 0.60 (0.3 0.49 (0.2) 1.46 (1.2) 1.46 (1.2) 1.44 (1.0) 1.48 (1.0) 1.48 (1.0) 0.59 (0.3 1.41 (1.0) 0.59 (0.5) 0.60 (0.8) 0.60 (0.8)	Weight% 7, 2:59 1.46 3,3.90 1.72 3,3.90 1.72 1,120 2.63 1,120 2.63 1,120 2.65 3,3.90 3.20 7,1.35 1.61 5,241 5.30 7,1.69 8.43 1,120 2.48 5,1.11 1.57 1,2.23 1.82 5,1.31 1.01 5,1.31 1.01 5,1.07 8.94
Study Milan(M),2003 Milan(M),2003 Hagstromer–N,2005 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–M,2010 Jensen–B,2012 Jensen–B,2012 Jensen–B,2012 Hajdarbegovic,2014 Marasigan,2017 Mansfield–UN 2020 Mansfield–UN 2020	ES (95% Cl) 1.10 (0.4 1.80 (0.8 0.60 (0.3) 2.40 (1.4 0.49 (0.2) 4.1.74 (1.22 4.1.74 (1.22) 4.1.74 (1.22	Weight% 7, 2.59 1.46 3, 3.90 1.72), 2.60 2.63), 1.20 2.65), 3.90 3.20 , 1.31 5.30 , 7, 1.59 8.43), 1.20 2.48 , 7, 1.59 8.43), 5.11 1.57), 2.23 1.82 5, 1.31 1.01 5, 1.40 9.67
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Hajdarbegovic,2014 Marasigan,2017 Mansfield–UN,2020 Mansfield–UN,2020	ES (95% CI) 1.10 (0.4 1.80 (0.8 1.50 (0.8(0.60 (0.3(0.49 (0.2) 1.74 (1.2) 1.74 (1.2) (1	Weight% 7, 2:59 1.46 3, 3:90 1.72 3, 3:90 1.72 2, 2:63 2.63 0, 1.20 2.05 1, 3:90 3.20 7, 1.35 1.61 5, 2.41 5.30 7, 1.459 8.43 0, 1.02 2.48 1, 1.69 8.43 1, 1.69 8.43 1, 1.69 8.43 5, 1.51 1.57 5, 2.31 1.61 5, 1.31 1.01 5, 1.31 9.67 5, 1.31 9.67
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Hajdarbegovic,2014 Marasigan,2017 Mansfield–UN,2020 Mansfield–UN,2020 Mansfield–UN,2020 Mansfield–UN,2020	ES (95% Cl)	Weight% 7, 2:59 1.46 3,3.90 1.72),2.60 2.63),1.20 2.63),1.20 2.65),3.90 3.20 ,1.33 1.61 ,5,241 5.30 7,1.69 8.43),1.20 2.48 7,1.83 6.25 5,1.31 1.67),2.23 1.82 5,1.31 1.01 5,1.07 8.94 5,1.14 9.67 4,0.93 4.66
Study Milan(M),2003	ES (95% Cl) 1.10 (0.4 1.80 (0.8 0.60 (0.3 0.60 (0.3 0.60 (0.3 0.49 (0.2 1.74 (1.2 1.74 (1.2 1.74 (1.2 0.59 (0.3 1.44 (1.0 0.59 (0.3 1.44 (1.0 0.59 (0.3 1.44 (1.0 0.59 (0.3 1.44 (1.0 0.59 (0.3 1.10 (0.4 0.64 (0.4 1.71 (0.9 0.64 (0.4 1.77 (0.9 0.65 (0.3 0.64 (0.4 1.77 (0.9 0.64 (0.4 1.77 (0.9 0.64 (0.4 1.77 (0.9 0.65 (0.3 0.64 (0.4 1.77 (0.9 0.65 (0.3 0.65 (0.3 0.75 (0.3 0.65 (0.5	Weight% 7, 2.59] 1.46 3, 3.90) 1.72), 2.60) 2.63), 1.20) 2.65), 3.90) 3.20 , 1.30) 3.20 , 1.31) 5.30 , 7, 1.59) 8.43), 1.02) 2.48 , 1.69) 8.43), 1.02) 2.48 , 1.57 5.11 , 5.111 1.57 , 5, 1.31) 1.01 5, 1.07) 8.94 , 0.93) 4.66 , 1.38) 8.04 , 1.33) 8.04
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Hajdarbegovic,2014 Marasigan,2017 Mansfield–UN,2020 Mansfield–DN,2020 Mansfield–DN,2020 Subtotal (I–squared = 76.8%, p = 0.000)	ES (95% CI) 1.10 (0.4 1.80 (0.8 1.50 (0.8(0.60 (0.3(0.49 (0.2) 1.44 (1.2) 1.44 (1	Weight% 7, 2:59 1.46 3, 3:90 1.72 3, 3:90 1.72 2, 2:63 2.63 0, 1.20 2.05 1, 3:90 3.20 1, 1.20 2.05 1, 3:90 3.20 1, 1.20 2.05 1, 3:9 8.43 0, 1.02 2.48 1, 1.59 8.43 0, 1.69 8.43 1, 1.69 8.43 1, 1.69 8.43 1, 1.83 1.87 1, 5, 1.11 1.57 1, 2.33 1.82 1, 1.01 5, 1.11 5, 1.13 1.01 5, 1.14 9.67 1, 0.93 4.66 1, 1.32 70.82
Study Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Hagstromer–M, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–M, 2012 Jensen–B, 2012 Jensen–S, 2012 Hajdarbegovic, 2014 Marasigan, 2017 Mansfield–UN, 2020 Mansfield–DN, 2020 Subtotal (I–squared = 76.8%, p = 0.000)	ES (95% Cl)	Weight% 7, 2:59 1.46 3, 3:90 1.72 3, 3:90 1.72 2.63 2.63 , 1.20 2.05 , 3:90 3.20 , 1.20 2.63 , 1.20 2.65 , 3:90 3.20 , 1.20 2.65 , 5, 241 5.30 7, 1.69 8.43 , 1.20 2.48 , 1.20 2.48 , 1.49 2.48 , 5, 1.11 1.57 , 2.23 1.82 , 5, 1.31 1.01 , 5, 1.71 1.57 , 5, 1.71 9.67 , 6, 0.73 4.66 , 1.14) 9.67 , 1.32 70.82
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Hajdstrogovic,2014 Marasigan,2017 Mansfield–UN,2020 Mansfield–DN,2020 Mansfield–DN,2020 Mansfield–DN,2020 Mansfield–DN,2020 Mansfield–DN,2020 Mansfield–DN,2020 Mansfield–DN,2020 Mansfield-DN,2020 Mansfield-DN,2020 Mansfield-DN,2020 Mansfield-DN,2020 Mansfield-DN,2020 Mansfield-DN,2020 Mansfield-DN,2020 Mansfield-DN,2020 Mansfield-DN,2020 Subtotal (I-squared = 76.8%, p = 0.000)	ES (95% Cl)	Weight% 7, 2.59 1.46 3, 3.90 1.72), 2.60 2.63), 1.20 2.63), 1.20 2.65), 3.90 3.20 , 1.35 1.61 , 5.241 5.30 7, 1.69 8.43), 1.20 2.48 , 1.30 5.511), 5.111 1.57), 2.23 1.82 , 1.31 1.01 , 5, 1.31 9.67 4, 0.93 4.66 , 1.32 70.82 - -
Study Milan(M),2003 Milan(F),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Jensen–B,2012 Jensen–S,2012 Hajdarbegovic,2014 Marasigan,2017 Mansfield–UN,2020 Mansfield–DN,2020 Subtotal (I–squared = 76.8%, p = 0.000) Ming,2004	ES (95% CI) 1.10 (0.4 1.80 (0.8 1.50 (0.8(0.60 (0.3(0.40 (0.2) 0.49 (0.2) 1.44 (1.2) 1.44 (1	Weight% 7, 2:59 1.46 3, 3:90 1.72 3, 3:90 1.72 2, 2:05 1.46 3, 3:90 1.72 2, 2:05 1.3:00 3, 1.20 2.05 3, 3:90 3.20 7, 1.20 2.05 3, 3:90 3.20 7, 1.35 1.61 5, 2.41 5.30 7, 1.83 6.25 3, 5.11 1.57 3, 2.33 1.82 5, 1.31 1.01 5, 1.31 1.01 5, 1.31 9.67 4, 0.93 4.66 3, 1.32 70.82 7, 1.88 6.76 3, 2.20) 0.80
Study Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Hagstromer–M, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–M, 2012 Jensen–B, 2012 Jensen–S, 2012 Hajdarbegovic, 2014 Marasigan, 2017 Marasigan, 2017 Mansfield–UN, 2020 Mansfield–DN, 2020 Subtotal (I–squared = 76.8%, p = 0.000) Ming, 2004 EI–Zein, 2010 Jankovic, 2010 Darmo 2012	ES (95% Cl) 1.10 (0.4 1.80 (0.8 0.60 (0.33 2.40 (1.4 0.49 (0.2) 1.46 (1.22 1.46 (1.22 1.46 (1.22 1.46 (1.22 1.46 (1.22 1.46 (0.12 1.46 (0.12 0.59 (0.33 1.10 (1.06 0.46 (0.14 0.46 (0.16 0.46 (0.16) 0.46 (0.16)	Weight% 7, 2:59 1.46 3, 3:90 1.72 3, 3:90 1.72 2, 2:63 2.63 3, 1.20 2.05 3, 3:90 3.20 7, 1.23 1.61 5, 1.20 2.05 3, 3:90 3.20 7, 1.23 1.61 5, 1.31 1.61 5, 1.31 1.01 5, 1.31 1.01 5, 1.31 1.01 5, 1.31 9.67 6, 1.38 8.04 1, 1.32 70.82 2.220 0.80 3, 1.39 1.30 5, 2.23 9.22
Study Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–M, 2012 Jensen–M, 2012 Jensen–S, 2012 Hajdsrbegovic, 2014 Mansfield–UM, 2020 Mansfield–UN, 2020 Mansfield–DN, 2020 Mansfield–DN, 2020 Subtotal (I–squared = 76.8%, p = 0.000) Ming, 2004 EI–Zein, 2010 Jankovic, 2010 Jankovic, 2010 Charge, S, 2015	ES (95% Cl)	Weight% 7, 2.59 1.46 3, 3.90 1.72), 2.60 2.63), 1.20 2.63), 1.20 2.63), 1.20 2.63), 3.90 3.20 , 1.35 1.61 , 5, 241 5.30 7, 1.69 8.43), 1.02 2.48 7, 1.69 8.43), 1.20 2.48 7, 1.59 8.23), 5.11 1.57), 2.23 1.82 , 1.31 1.01 5, 1.14 9.67 4, 0.93 4.66 0, 1.38 8.04 1, 1.32 70.82 7, 1.08 6.76 0, 2.20 0.80 3, 11.39 1.10 3, 2.32 4.26
Study Milan(M),2003 Milan(K),2003 Hagstromer–N,2005 Hagstromer–M,2005 Olesen,2005 Synnerstad,2008 Arana–N,2010 Arana–N,2010 Jensen–B,2012 Jensen–B,2012 Jensen–S,2012 Hajdarbegovic,2014 Marasigan,2017 Mansfield–UN,2020 Mansfield–DN,2020 Mansfield–DN,2020 Subtotal (I–squared = 76.8%, p = 0.000) Ming,2004 EI–Zein,2010 Jankovic,2010 Dyer,2012 Cheng–S,2015 Cheng–S,2015	ES (95% CI) 1.10 (0.4 1.80 (0.8 1.50 (0.8 0.60 (0.3 0.60 (0.3 0.40 (0.4 0.49 (0.2 1.44 (1.2 0.59 (0.3 1.41 (1.0 0.46 (0.1 0.46 (0.1 0.47 (0.1))))))))))))))))))))))))))))))))))))	Weight% 7, 2:59 1.46 3, 3:90 1.72 3, 3:90 1.72 2, 2:63 2.63 0, 1.20 2.05 1, 3:90 3.20 1, 1.20 2.05 1, 3:90 3.20 1, 1.20 2.05 1, 3:0 3.30 1, 1.20 2.05 1, 1.40 5.30 7, 1.55 1.61 5, 2.41 5.30 7, 1.83 6.25 5, 5.11 1.57 7, 1.23 1.82 5, 1.31 1.01 5, 1.31 1.01 5, 1.31 9.46 1, 1.32 70.82 7, 1.88 6.67 0, 2.20 0.80 1, 1.32 70.82 7, 1.08 6.76 0, 2.20 0.80 1, 3.39 1.01 5, 2.35 2.35
Study Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Hagstromer–M, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–M, 2012 Jensen–B, 2012 Jensen–B, 2012 Marasigan, 2017 Marasigan, 2017 Marasfield–UN, 2020 Mansfield–DN, 2020 Subtotal (I–squared = 76.8%, p = 0.000) Ming, 2004 EI–Zein, 2010 Jankovic, 2010 Darkovic, 2015 Cheng–B, 2015 Cheng–B, 2015 Cheng–B, 2018	ES (95% C1) 1.10 (0.4 1.80 (0.8 1.50 (0.8 0.60 (0.33 2.40 (1.4 0.49 (0.2) 1.46 (1.2) 1.46 (1.2) 2.48 (1.00 2.48 (1.00 1.46 (0.12) 2.48 (1.00 1.05 (0.56 0.46 (0.12) 0.46 (0.12) 0.47 (0.2) 0.47 (0	Weight% 7, 2:59 1.46 3, 3.90 1.72 3, 3.90 1.72 2, 63 1.72 3, 3.90 1.72 2, 63 1.72 3, 1.20 2.63 3, 1.20 2.63 3, 1.20 2.63 3, 1.20 2.64 5, 1.31 1.61 5, 1.31 1.67 7, 1.83 6.25 5, 1.31 1.01 5, 1.31 1.01 5, 1.31 1.01 5, 1.31 1.01 5, 1.31 9.67 1, 0.33 4.66 1, 1.32 70.82 2 - 2 - 2 - 3, 1.39 1.00 3, 2.200 0.80 3, 1.319 1.01 5, 2.233 1.20 3, 2.200 0.80 3, 1.39 1.01 5, 2.231 2.23 7, 3.45 <t.< td=""></t.<>
Study Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Hagstromer–M, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–M, 2012 Jensen–B, 2012 Jensen–S, 2012 Hajdarbegovic, 2014 Mansfield–UM, 2020 Mansfield–UM, 2020 Mansfield–UM, 2020 Mansfield–UN, 2020 Mansfield–Stragender Jesupponder El-Zein, 2010 Jankovic, 2010 Jankovic, 2010 Dyarv, 2015 Cheng–S, 2015 Cheng–S, 2015 D'Arv, 2019	ES (95% Cl) 1.10 (0.4 1.00 (0.3 1.50 (0.8 0.60 (0.3 0.60 (0.3 0.60 (0.3 0.49 (0.2) 1.44 (1.2) 0.59 (0.3 1.44 (1.2) 0.59 (0.3 0.46 (0.10 0.46 (0.10 0.45 (0.46 (0.10 0.45 (0.46 (0.10 0.45 (0.46 (0.10 0.45 (0.10 0.15 (0.10) 0.45 (0.10)	Weight% 7, 2:59 1.46 3, 3:90 1.72), 2:60 2.63), 1.20 2.05), 3:90 3.20 , 1.33 1.61), 1.20 2.05), 3:90 3.20 , 1.35 1.61 , 1.32 2.48 , 1.49 8.43), 1.20 2.48 , 1.32 1.82 , 5, 1.11 1.57 , 2.23 1.82 , 5, 1.71 8.94 , 5, 1.71 8.94 , 1.32 7.082 7, 1.08 6.76 , 2.20 0.80 , 1.132 7.082 7, 3.45 2.35 7, 3.01 2.10 , 2.35 3.19
Study Milan(M), 2003 Milan(K), 2003 Hagstromer–N, 2005 Hagstromer–N, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–B, 2012 Jensen–B, 2012 Jensen–S, 2012 Hajdarbegovic, 2014 Marasigan, 2017 Mansfield–UN, 2020 Mansfield–DN, 2020 Mansfield–DN, 2020 Subtotal (I–squared = 76.8%, p = 0.000) Ming, 2004 EI–Zein, 2010 Jankovic, 2012 Cheng–S, 2015 Cheng–S, 2015 Cheng–S, 2015 Subtotal (I–squared = 67, 2%, p = 0.003)	ES (95% CI) 1.10 (0.4 1.00 (0.8 1.50 (0.8 0.60 (0.3 0.60 (0.3 0.40 (0.4 0.49 (0.2 1.74 (1.2 1.46 (1.2 0.59 (0.3 1.41 (1.0 2.48 (1.0 0.46 (0.16 0.96 (0.86 1.10 (1.0 0.66 (0.4 0.96 (0.86 1.10 (1.0 0.65 (0.5 0.64 (0.4 1.17 (0.95 0.65 (0.66 0.64 (0.4 1.17 (0.95 0.65 (0.66 0.64 (0.4 1.17 (0.95 0.65 (0.66 0.64 (0.42 1.15 (1.0 1.55 (1.0 1.55 (1.0 1.55 (1.0 1.55 (1.0) 1.55 (1.0) 1.	Weight% 7, 2:59 1.46 3, 3:90 1.72 3, 3:90 1.72 2, 2:60 2.63 0, 1.20 2.05 1, 3:90 3.20 1, 1.20 2.05 1, 3:90 3.20 1, 1.20 2.05 1, 3:90 3.20 1, 1.20 2.05 1, 1.20 2.05 1, 1.20 2.05 1, 1.49 8.43 1, 1.20 2.48 1, 1.83 6.25 1, 1.11 1.57 1, 2.33 1.82 1, 1.11 9.67 1, 0.93 4.66 1, 1.32 70.82 7, 1.080 6.76 1, 2.20 0.80 1, 1.32 7.010 2, 2.32 4.26 7, 3.011 2.10 5, 2.35 3.19 1, 1.22 8.63 1, 1.21 8.63
Study Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Hagstromer–M, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–M, 2012 Jensen–B, 2012 Jensen–S, 2012 Hajdarbegovic, 2014 Marasigan, 2017 Mansfield–UN, 2020 Mansfield–DN, 2020 Subtotal (I–squared = 76.8%, p = 0.000) Ming, 2004 EI–Zein, 2010 Jakovic, 2010 Jakovic, 2013 Cheng–B, 2015 Cheng–B, 2015 Cheng–B, 2015 Cheng–B, 2015 Orall B D'Arcy, 2019 Subtotal (I–squared = 67.2%, p = 0.003)	ES (95% CI) 1.10 (0.4 1.00 (0.4 1.00 (0.8 1.50 (0.8 0.60 (0.3 0.49 (0.2) 1.14 (1.2 1.46 (1.2) 1.46 (1.2) 1.46 (1.2) 1.46 (1.2) 1.46 (1.2) 1.46 (1.2) 1.46 (0.12) 1.46 (0.12) 1.17 (0.99) 1.15 (1.00) 1.52 (0.7) 1.52 (0.	Weight% 7, 2:59 1.46 3, 3.90 1.72 3, 3.90 1.72 3, 3.90 1.72 2, 63 1.61 3, 1.20 2.63 3, 1.20 2.63 3, 1.20 2.63 3, 1.20 2.63 3, 1.20 2.63 3, 1.20 2.64 5, 2.41 5.30 7, 1.69 8.43 9, 1.20 2.48 6, 1.69 8.43 9, 1.69 8.43 9, 1.69 8.43 9, 1.69 8.43 9, 1.69 8.43 9, 1.69 8.43 9, 1.10 1.57 9, 2.23 1.82 1, 1.14 9.67 9, 1.38 8.04 1, 1.32 70.82 7, 1.08 6.76 9, 2.20 0.80 8, 2.35 7, 3.01 7, 3.01 2.15 7, 3.01 2.10 <
Study Milan(M), 2003 Milan(F), 2003 Hagstromer–N, 2005 Hagstromer–M, 2005 Olesen, 2005 Synnerstad, 2008 Arana–N, 2010 Jensen–B, 2012 Jensen–B, 2012 Jensen–S, 2012 Hajdarbegovic, 2014 Maraigan, 2017 Mansfield–UN, 2020 Mansfield–UN, 2020 Mansfield–DN, 2020 Mansfield–DN, 2020 Mansfield–CN, 2020 Mansfield–CN, 2020 Mansfield–S, 2015 Cheng–S, 2015 Cheng–S, 2015 Cheng–S, 2015 Cheng–S, 2015 D'Arcy, 2019 Subtotal (I–squared = 67.2%, p = 0.003) Överail (I–squared = 73.4%, p = 0.000)	ES (95% Cl) 1.10 (0.4 1.00 (0.3 0.60 (0.3 0.60 (0.3 0.60 (0.3 0.49 (0.2) 1.46 (1.2) 1.46 (1.2) 1.46 (1.2) 0.59 (0.3 1.41 (1.0) 0.46 (0.10 0.46 (0.10 0.46 (0.10 0.46 (0.10 0.46 (0.10 0.46 (0.10 0.45 (0.46 (0.10) 0.45 (0.46 (0.10) 0.45 (0.46 (0.10) 0.45 (0.46 (0.10) 0.45 (0.46 (0.10) 0.45 (0.46 (0.10) 0.45	Weight% 7, 2:59 1.46 3, 3:90 1.72 3, 2:60 2.63 1, 1:20 2.63 1, 1:20 2.65 1, 3:90 3.20 7, 1:35 1.61 5, 2:41 5.30 7, 1:69 8.43 1, 1:20 2.48 5, 1:31 1.61 5, 1:31 1.67 1, 2:23 1.82 5, 1:31 1.01 5, 1:31 1.01 5, 1:31 1.01 5, 1:31 9.67 1, 1:32 70.82 7, 1.08 6.76 1, 1:32 70.82 7, 3.45 2.35 7, 3.01 2.10 5, 2.33 3.19 4, 1:22 8.63 2, 1.71 29.18 5, 1:32 100:00

b

subgroup analysis by study design. d Forest plot for subgroup analysis by region

Secondly, according to Fig. 2b, the pooled analysis indicated that AD was significantly associated with an increased risk of NMSC (OR 1.39, 95% CI 1.20–1.61, $P_{\text{heterogeneity}} = 0.000$, $I^2 = 72.7\%$). Further subgroup analyses with regard to specific NMSC type were performed to further explore the origin of heterogeneity; we

a		
Study	ES (95% CI) W	eight%
Milan(M),2003 Milan(F),2003	1.10 (0.47, 2.59) 1.80 (0.83, 3.90)	2.46 2.88
Jankovic,2010	4.17 (1.53, 11.39)	1.86
Jensen-B.2012	1.54(1.03, 2.32) 1 41 (1 07, 1 83)	0.94
Cheng-B,2015	1.52 (0.77, 3.01)	3.52
Subtotal	\bigcirc BCC 1.51 (1.24, 1.84)	27.58
(I-squared = 0.0%, p = 0.426)		
Ming,2004	0.85 (0.67, 1.08)	10.67
Hagstromer-N,2005	1.50 (0.80, 2.60)	4.36
Olesen,2005	2.40 (1.40, 3.90)	5.27
Arana-N,2010	1.46 (1.27, 1.69)	13.04
Mansfield-UN,2020	• 1.10 (1.06, 1.14)	14.76
Mansfield-DN,2020	1.17 (0.99, 1.38)	12.50
Subtotal	NMSC 1.23 (1.03, 1.47)	60.59
(I-squared = 82.8%, p = 0.000)		
Jensen-S,2012	2.48 (1.00, 5.11)	2.65
Cheng-S,2015	1.83 (0.97, 3.45)	3.92
Cho,2018	1.75 (1.05, 2.93)	5.26
Subtotal	SCC 1.90 (1.33, 2.72)	11.83
(I-squared = 0.0%, p = 0.770)		
Overall	1.39 (1.20, 1.61)	100.00
(I-squared = 72.7%, p = 0.000)		
.0878	1 11.4	-

C Study	ES (95% CI) We	eight%
 Milan(M),2003 Milan(F),2003 Dyer,2012 Jensen-B,2012 Subtotal (I-squared = 0.0%, p = 0.843)	1.10 (0.47, 2.59) 1.80 (0.83, 3.90) 1.54 (1.03, 2.32) 1.41 (1.07, 1.83) BCC 1.45 (1.17, 1.78)	2.11 2.48 6.01 8.64 19.24
Hagstromer-N,2005 Olesen,2005 Arana-N,2010 Mansfield-UN,2020 Mansfield-DN,2020 Subtotal (I-squared = 83.2%, p = 0.000)	1.50 (0.80, 2.60) 2.40 (1.40, 3.90) 1.10 (1.06, 1.14) 1.17 (0.99, 1.38) NMSC 1.33 (1.10, 1.61)	3.76 4.55 11.43 12.98 10.94 43.65
 Hagstromer-M,2005 Synnerstad,2008 Arana-M,2010 Jensen-M,2012 Mansfield-UM,2020 Subtotal (I-squared = 79.2%,p = 0.000)	0.60 (0.30, 1.20) 0.49 (0.27, 1.35) 1.74 (1.25, 2.41) 0.59 (0.30, 1.02) 0.96 (0.86, 1.07) 0.64 (0.44, 0.93) Melanoma 0.82 (0.58, 1.16)	2.95 2.32 7.39 3.56 12.07 6.54 34.84
Jensen-S.2012 Subtotal (I-squared = .%, p = .)	2.48 (1.00, 5.11) 	2.27 2.27
Overall (I–squared = 78.1%, p = 0.000)	1.19 (1.04, 1.37)	100.00
.178	1 5.61	



found that AD was significantly increased with an increased risk of BCC (OR 1.51, 95% CI 1.24–1.84, $P_{\text{heterogeneity}} = 0.426$, $I^2 = 0.0\%$) and SCC (OR 1.90, 95% CI 1.33-2.72, Pheterogene- $_{itv} = 0.770, I^2 = 0.0\%$) (Fig. 3a). With regard to study design, AD was significantly increased with an increased risk of NMSC in cohort study subgroup (OR 1.39, 95% CI 1.19-1.63, Phetero- $_{\text{geneity}} = 0.000, I^2 = 73.2\%$ (Fig. 3b).

Thirdly, according to Fig. 2c, AD was significantly associated with an increased risk of



c Forest plot for subgroup analysis of cohort studies by cancer type. d Forest plot for subgroup analysis of cohort studies by region

5.11

(I-squared = 78.1%, p = 0.000) .196

overall skin cancer in cohort subgroups (OR 1.19, 95% CI 1.04–1.37). Further subgroup analyses were performed by specific cancer type, and the pooled analysis of cohort studies indicated that AD was significantly associated with an increased risk of BCC (OR 1.45, 95% CI 1.17-1.78) and SCC (OR 2.48, 95% CI 1.10–5.61), but not melanoma (Fig. 3c). According to region, the pooled analysis of cohort studies indicated that AD was statistically associated with an increased risk of skin



Meta-analysis estimates (with omission of the indicated study)

Fig. 4 Sensitivity analysis regarding the association between AD and skin cancer

cancer in Europe (OR 1.17, 95% CI 1.02–1.35) and America (OR 1.54, 95% CI 1.03–2.31) (Fig. 3d).

Lastly, to assess the stability of our results, sensitivity analysis was conducted, and revealed that excluding each study in turn did not alter the overall combined results (Fig. 4). Publication bias was evaluated following Beggar's rank correlation and Egger's linear regression tests, which indicated that no publication bias existed among the studies (Beggar's: P > |z| = 0.981; Egger's: P = 0.746, 95% CI -0.564 to 1.408) (Fig. 5).

DISCUSSION

We reviewed the epidemiological evidence on the association between atopic dermatitis and skin cancer risk, and pooled this analysis. The study showed that AD was significantly associated with an increased risk of overall skin cancer. Moreover, sensitivity analysis by excluding each study in turn demonstrated stable consequence, and no publication bias existed among the included studies. Therefore, the outcome was robust and reliable, and regular skin cancer screenings are recommended for patients with AD.

Furthermore, we performed subgroup analyses to assess the association between AD and skin cancer, and to explore the origin of heterogeneity. According to cancer type, AD was associated with a significantly elevated risk of NMSC, but with a nonsignificant decreased risk of melanoma. However, the review by Karim et al. showed that allergic diseases appeared to reduce the risk for developing melanoma and NMSC [29]. Our outcomes were more credible. Possible reasons may be that our pooled analysis included some more eligible

а

Funnel plot with pseudo 95% confidence limits



С

Begg's funnel plot with pseudo 95% confidence limits



Fig. 5 Publication bias among the studies indicating the association of AD with skin cancers. a Funnel plot indicating the lack of publication bias among the studies.

studies on the association between skin cancers and AD.

According to study design, only the pooled analyses of cohort studies demonstrated AD increasing skin cancer risk. This was more credible, because the design of cohort studies is from cause to effect, with strong ability to demonstrate causality, high quality of evidence, and better confirmation of the etiological hypothesis. According to region, AD was significantly associated with an increased risk of skin cancer in both Europe and America. The above results suggest that different study designs and regions might affect the stability of the association between AD and skin cancer risk. Unfortunately, we did not discover the

b

Begg	's Test						
adj	. Kendall's	Score (P-Q)	=	2			
	Std. D	ev. of Score	= 42	.82			
	Numb	er of Studies	= 2	25			
		Z	= 0.	05			
		Pr > z	= 0.9	963			
		Z	= 0.	.02 (con	tinuity corre	cted)	
		Pr > z	= 0.9	981 (coi	ntinuity corre	ected)	
Egge	Egger's test						
Std_Ef	f Coef.	Std. Err.	t	P> t	[95% Cor	nf. Interval]	
slope bias	.0856593 .4217274	.0372159 .4767066	2.30 0.88	0.031 0.385	.0086725 5644153	.1626462 1.40787	

d

Egger's publication bias plot



b-**d** Beggar's and Egger's tests indicating the lack of publication bias among the studies

origin of heterogeneity. Therefore, the results should be interpreted with caution.

Further analyses found that AD was statistically associated with an increased risk of basal cell carcinoma and squamous cell carcinoma. This conclusion was similar to that of Jensen et al. [6]. However, this result was not consistently supported by Cheng et al.'s study [15].

Unfortunately, it is unclear why skin cancer risk would be increased in patients affected by AD. One reason might be that patients with AD often receive phototherapy, and phototherapy has been linked with various skin cancers [30]. Additionally, patients with AD often require more skin-related tests associated with an increased risk of skin cancer [31]. Atopic dermatitis and other inflammatory skin diseases provide more convincing evidence.

skin cancer progression [32]. This study has several limitations. First, substantial heterogeneity was inevitable. Second, adjustment factors varied among different studies, and this may have contributed to some uncertainty regarding the estimates. Third, all included studies were from Europe and America, and non-Western studies are required to

CONCLUSIONS

In conclusion, this study demonstrated that AD was significantly associated with an increased risk of skin cancer, basal cell carcinoma, and squamous cell carcinoma. Further studies, including well-designed, worldwide trials (especially prospective, non-Western studies), are required to provide more convincing evidence. At the same time, the mechanism of AD leading to skin cancer is not clear, and further research is needed to explore the possibility of a potential link or a common pathogenesis.

ACKNOWLEDGEMENTS

Funding. This project was funded by the National Natural Science Foundation of China (no. 81760136, 81860553); the Ten-thousand Talents Program of Yunnan Province (no. YNWR-MY-2018-039); the Medical Leadership Foundation of Health and Family Planning Commission of Yunnan Province, China (no. L-201613): the Yunnan Province Clinical Research Center for Skin Immune Diseases (no. 2019ZF012); and the Yunnan Province Clinical Center for Skin Immune Diseases (no. ZX2019-03-02). The journal's Rapid Service Fee was funded by the authors.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of

the work as a whole, and have given their approval for this version to be published.

Author Contributions. Dr. Yuye Li had full access to all the data in the study and takes responsibility for their integrity along with the accuracy of the analyses. Conception and design: Yun Zhu and Yuye Li. Acquisition, analysis, or interpretation of data: all named authors (Yun Zhu, Hongmei Wang, Juan He, Luhui Yang, Xiaoyan Zhou, Zhe Li, Huiling Zhou, Huadi Zhao, and Yuye Li). Drafting of the manuscript: Yun Zhu. Critical revision of the manuscript for important intellectual content: Yun Zhu and Yuye Li. Statistical analysis: Yun Zhu.

Disclosures. Yun Zhu, Hongmei Wang, Juan He, Luhui Yang, Xiaoyan Zhou, Zhe Li, Huiling Zhou, Huadi Zhao, and Yuye Li have nothing to disclose.

Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Data Availability Statement. All data generated or analyzed during this study are included in this published article/as supplementary material.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

- 1. Berke R, Singh A, Guralnick M. Atopic dermatitis: an overview. Am Fam Physician. 2012;86(1):35–42.
- Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94.
- 3. Wang L, Bierbrier R, Drucker AM, et al. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and metaanalysis. JAMA Dermatol. 2020;156(2):158–71.
- 4. Vineis P, Crosignani P, Sacerdote C, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Commun Health. 2000;54(6):431–6.
- Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56–66.
- Jensen AO, Svaerke C, Körmendiné Farkas D, et al. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977–2006). Am J Clin Dermatol. 2012;13(1):29–36.
- Hagströmer L, Ye W, Nyrén O, et al. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005;141(9):1123–7.
- Cho JM, Davis DMR, Wetter DA, et al. Association between atopic dermatitis and squamous cell carcinoma: a case-control study. Int J Dermatol. 2018;57(3):313-6.
- Milán T, Verkasalo PK, Kaprio J, et al. Lifestyle differences in twin pairs discordant for basal cell carcinoma of the skin. Br J Dermatol. 2003;149(1): 115–23.
- 10. Ming ME, Levy R, Hoffstad O, et al. The lack of a relationship between atopic dermatitis and nonmelanoma skin cancers. J Am Acad Dermatol. 2004;50(3):357–62.
- 11. El-Zein M, Parent ME, Kâ K, et al. History of asthma or eczema and cancer risk among men: a population-based case-control study in Montreal, Quebec, Canada. Ann Allergy Asthma Immunol. 2010;104(5):378–84.

- 12. Janković S, Maksimović N, Janković J, et al. Risk factors for basal cell carcinoma: results from the case–control study. Central Eur J Med. 2010;5(6): 666–73.
- 13. Dyer RK, Weinstock MA, Cohen TS, et al. Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. J Invest Dermatol. 2012;132(11):2544–51.
- 14. Hajdarbegovic E, Atiq N, van der Leest R, et al. Atopic dermatitis is not a protective factor for melanoma but asthma may be. Int J Clin Oncol. 2014;19(4):708–11.
- 15. Cheng J, Zens MS, Duell E, et al. History of allergy and atopic dermatitis in relation to squamous cell and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev. 2015;24(4):749–54.
- 16. Marasigan V, Morren MA, Lambert J, et al. Inverse association between atopy and melanoma: a case–control study. Acta Derm Venereol. 2017;97(1):54–7.
- 17. D'Arcy M, Rivera DR, Grothen A, et al. Allergies and the subsequent risk of cancer among elderly adults in the United States. Cancer Epidemiol Biomarkers Prev. 2019;28(4):741–50.
- 18. Mansfield KE, Schmidt SAJ, Darvalics B, et al. The association between atopic eczema and cancer in England and Denmark: two cohort studies. Pharmacoepidemiol Drug Saf. 2019;28:11.
- 19. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
- 20. Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
- 21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
- 22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
- 23. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19(4): 251–3.
- 24. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.

- 25. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
- 26. Olesen AB, Engholm G, Storm HH, et al. The risk of cancer among patients previously hospitalized for atopic dermatitis. J Invest Dermatol. 2005;125(3): 445–9.
- 27. Synnerstad I, Fredrikson M, Ternesten-Bratel A, et al. Low risk of melanoma in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(12):1423–8.
- 28. Arana A, Wentworth CE, Fernández-Vidaurre C, et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the UK. Br J Dermatol. 2010;163(5):1036–43.

- 29. Karim AF, Westenberg LEH, Eurelings LEM, et al. The association between allergic diseases and cancer: a systematic review of the literature. Neth J Med. 2019;77(2):42–66.
- 30. Lam M, Zhu JW, Tadrous M, et al. Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2021;157(5): 549–58.
- 31. Mansfield KE, Schmidt SAJ, Darvalics B, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156(10):1086–97.
- 32. Woo YR, Cho SH, Lee JD et al. The human microbiota and skin cancer. Int J Mol Sci 2022; 23(3).